Evidence map›Paper›PMID 28379093›Full record

ArticlemAbs2017

Single amino acid substitution in LC-CDR1 induces Russell body phenotype that attenuates cellular protein synthesis through eIF2α phosphorylation and thereby downregulates IgG secretion despite operational secretory pathway traffic.

Haruki Hasegawa, Ann Hsu, Christine E Tinberg, Karen E Siegler, Aaron A Nazarian, Mei-Mei Tsai

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Haruki Hasegawaa Department of Therapeutic Discovery , Amgen Inc. , South San Francisco , CA , USA.ORCID 0000-0002-3464-4715
Ann Hsub Department of Therapeutic Discovery , Amgen Inc. , Thousand Oaks , CA , USA.
Christine E Tinberga Department of Therapeutic Discovery , Amgen Inc. , South San Francisco , CA , USA.ORCID 0000-0002-6179-0435
Karen E Sieglerc Department of Cardiometabolic Disorders , Amgen Inc. , South San Francisco , CA , USA.
Aaron A Nazarianb Department of Therapeutic Discovery , Amgen Inc. , Thousand Oaks , CA , USA.ORCID 0000-0001-7531-6040
Mei-Mei Tsaib Department of Therapeutic Discovery , Amgen Inc. , Thousand Oaks , CA , USA.ORCID 0000-0002-3052-7853
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amino acid sequence differences in the variable region of immunoglobulin (Ig) cause wide variations in secretion outputs. To address how a primary sequence difference comes to modulate Ig secretion, we investigated the biosynthetic process of 2 human IgG2κ monoclonal antibodies (mAbs) that differ only by one amino acid in the light chain complementarity-determining region 1 while showing ∼20-fold variance in secretion titer. Although poorly secreted, the lower-secreting mAb of the 2 was by no means defective in terms of its folding stability, antigen binding, and in vitro biologic activity. However, upon overexpression in HEK293 cells, the low-secreting mAb revealed a high propensity to aggregate into enlarged globular structures called Russell bodies (RBs) in the endoplasmic reticulum. While Golgi morphology was affected by the formation of RBs, secretory pathway membrane traffic remained operational in those cells. Importantly, cellular protein synthesis was severely suppressed in RB-positive cells through the phosphorylation of eIF2α. PERK-dependent signaling was implicated in this event, given the upregulation and nuclear accumulation of downstream effectors such as ATF4 and CHOP. These findings illustrated that the underlining process of poor Ig secretion in RB-positive cells was due to downregulation of Ig synthesis instead of a disruption or blockade of secretory pathway trafficking. Therefore, RB formation signifies an end of active Ig production at the protein translation level. Consequently, depending on how soon and how severely an antibody-expressing cell develops the RB phenotype, the productive window of Ig secretion can vary widely among the cells expressing different mAbs.

Indexed as

Amino Acid SubstitutionProtein BiosynthesisSecretory PathwayAnimalsComplementarity Determining RegionsEukaryotic Initiation Factor-2HEK293 CellsHumansImmunoglobulin GMicePhosphorylationComplementarity Determining RegionsEukaryotic Initiation Factor-2Immunoglobulin GeIF2αendoplasmic reticulumimmunoglobulinprotein translationRussell bodysingle amino acid substitution

Identifiers

PMID28379093
PMCPMC5524154
OpenAlexW2605048294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.